Eikon Therapeutics
Series D in 2025
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
Atrandi Biosciences
Series A in 2025
Atrandi Biosciences is a biotechnology company focusing on next-generation single-cell technology, specifically single-cell eukaryotic DNA sequencing. This innovative approach enables the analysis of genomic alterations and cellular heterogeneity.
Frontera Health
Seed Round in 2025
Frontera Health is changing autism care in underprivileged regions with AI-powered tools that assist physicians in evaluating and treating children with autism and related diseases.
Bluenote Health
Venture Round in 2024
Bluenote Health operates as an AI platform for life sciences.
Cala Health
Series C in 2024
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.
Enveda Biosciences
Series C in 2024
Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.
Maven Clinic
Series F in 2024
Maven Clinic is an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and the postpartum period. Founded in 2014 and headquartered in New York City, the clinic provides video appointments and private messaging with a network of women's and family health practitioners. Its comprehensive services cater to various needs, including IVF and egg-freezing tracks, pregnancy, postpartum, partner support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and customized training for human resources managers. The company serves individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care solutions.
JOYA is the first employee skincare and wellness benefit platform. The company's goal is to provide tailored access to services such as skin cancer screenings, skin condition treatment, anti-aging, acne, and hair loss care from reputable physicians at an accessible cost.
Mendaera is a medtech startup specializing in advanced healthcare technologies, focusing on robotics and diagnostic tools. Its platform integrates robotics, AI, real-time imaging, and connectivity to enable consistent medical interventions at scale, aiming to make high-quality care accessible to all patients.
Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.
Feeling Great
Seed Round in 2024
Feeling Great is a digital health company that specializes in mental health support. It offers an app featuring an AI-powered chatbot, interactive courses, self-help exercises, and evidence-based treatment information. The platform aims to help individuals manage depression and anxiety, build coping mechanisms, and enhance overall well-being.
Summer Health
Series A in 2024
Summer Health facilitates convenient access to high-quality healthcare professionals via text messaging. It provides expert advice and reliable answers to users' health concerns.
Vesta Healthcare
Venture Round in 2024
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.
Waymark
Venture Round in 2023
Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.
Mendaera is a medtech startup specializing in advanced healthcare technologies, focusing on robotics and diagnostic tools. Its platform integrates robotics, AI, real-time imaging, and connectivity to enable consistent medical interventions at scale, aiming to make high-quality care accessible to all patients.
Daybreak Health
Series B in 2023
Founded in 2019, Daybreak Health specializes in providing online counseling services tailored for teenagers. Through its mobile app, the company connects teens with therapists who focus on issues such as anxiety, depression, stress management, and building self-esteem.
Siren Biotechnology
Seed Round in 2023
Siren Biotechnology is a biotechnology company focused on cancer treatment through an integrated therapeutic modality that combines adeno-associated virus–based gene therapy with cytokine immunotherapy. The approach delivers targeted cytokines to tumors, aiming to activate both innate and adaptive immune responses while addressing toxicity and off-target effects. By uniting gene delivery with immunotherapy in a single modality, the company seeks to enhance tumor cell elimination and improve long-term anti-tumor immunity, potentially reducing recurrence in cancer patients.
Thatch is a digital platform designed to streamline employee healthcare management for businesses. It offers an AI-driven assistant, ThatchBot, which provides round-the-clock support for employees' healthcare queries and expense tracking. The platform enables companies to set personalized healthcare budgets for each employee, fostering tailored healthcare experiences and efficient benefits navigation.
Thatch
Pre Seed Round in 2023
Thatch is a digital platform designed to streamline employee healthcare management for businesses. It offers an AI-driven assistant, ThatchBot, which provides round-the-clock support for employees' healthcare queries and expense tracking. The platform enables companies to set personalized healthcare budgets for each employee, fostering tailored healthcare experiences and efficient benefits navigation.
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials.
Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive.
The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders.
Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Enveda Biosciences
Series B in 2022
Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.
Fertilidad Integral
Venture Round in 2022
Fertilidad Integral is a fertility care provider focused on comprehensive treatments, including egg freezing, embryo freezing, in vitro fertilization, and intrauterine insemination. The company emphasizes patient-centered care with a focus on wellness and emotional support, offering therapy sessions with a specialist to accompany patients through their fertility journey. It combines clinical precision with compassionate, personalized guidance to help individuals and couples pursue family-building goals.
Cajal Neuroscience
Series A in 2022
Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.
Maven Clinic
Series E in 2022
Maven Clinic is an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and the postpartum period. Founded in 2014 and headquartered in New York City, the clinic provides video appointments and private messaging with a network of women's and family health practitioners. Its comprehensive services cater to various needs, including IVF and egg-freezing tracks, pregnancy, postpartum, partner support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and customized training for human resources managers. The company serves individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care solutions.
WellTheory
Seed Round in 2022
WellTheory operates a virtual care platform specializing in autoimmune and inflammatory conditions. It combines community support, dietary adjustments, lifestyle changes, and personalized insights to provide evidence-based recommendations for managing these conditions.
Trial Library
Seed Round in 2022
Trial Library is an oncology clinical trials company that focuses on improving health equity through its innovative clinical trial technology. The company aims to expand access to cancer precision medicine by creating inclusive research environments that enhance health outcomes. By addressing disparities in the discovery and access to cancer clinical trials, Trial Library seeks to transform the standard of care. Its technology assists in accelerating equitable recruitment for clinical trials, ensuring that a diverse patient population is represented in cancer research.
Summer Health
Seed Round in 2022
Summer Health facilitates convenient access to high-quality healthcare professionals via text messaging. It provides expert advice and reliable answers to users' health concerns.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
LatchBio is a biotechnology company founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman. It focuses on developing a data infrastructure aimed at supporting the open-source biocomputing revolution. The company provides a bioinformatics platform specifically designed for cell and gene therapy startups, offering a modern cloud computing stack that enables biotech labs to manage and execute custom workflows, pipelines, and machine learning models. This platform allows scientists to create bioinformatic queries efficiently, without requiring command-line expertise or the burdens of complex system setups. By streamlining data integration and computational processes, LatchBio helps biotech companies accelerate therapeutic discovery and reduce engineering costs.
Miga is a virtual cardiometabolic clinic offering a gamified mobile app for managing obesity, hypertension, diabetes, and hyperlipidemia. It combines clinical services such as labs, devices, pharmacy, and lifestyle coaching.
Alife Health
Series A in 2022
Alife Health develops artificial intelligence tools for fertility care to improve pregnancy outcomes. The company provides AI-based health technology that helps doctors select the healthiest embryos and supports IVF planning, aiming to increase the likelihood of healthy pregnancies. It connects fertility specialists with patients to streamline IVF treatment and decision making. Founded in 2020 and headquartered in San Francisco, California, the company focuses on applying deep learning and software to reproductive medicine, enabling clinicians to personalize embryo selection and patient care. Alife Health strives to enhance access to effective fertility treatments and assist prospective parents in achieving successful pregnancies.
Creyon Bio
Series A in 2022
Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.
Pawp
Venture Round in 2022
Pawp, Inc. is a digital health clinic and telehealth platform founded in 2020 and based in New York, New York. The company focuses on providing pet owners with 24/7 access to licensed veterinary professionals, enabling them to manage their pets' health effectively. Pawp's services aim to reduce unnecessary veterinary visits by offering expert consultations online, thereby lowering costs for pet owners. Additionally, the company provides a pet emergency fund of $3,000 per year, acting as a financial safety net for unforeseen veterinary expenses. By combining access to veterinary care and emergency funding, Pawp empowers pet owners to make informed health decisions for their pets.
Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.
Balanced
Seed Round in 2022
Balanced is a digital fitness company focused on healthy aging for older adults. It provides live exercise and mindfulness classes delivered via video, including Zoom, and offers a digital platform with physical therapy assessments, personalized workout schedules, and aging-focused fitness guidance. Founded in 2021 and headquartered in New York, United States, Balanced aims to help older adults maintain a healthy lifestyle through accessible, structured fitness and wellness programs.
Gandeeva Therapeutics
Series A in 2022
Gandeeva Therapeutics is a precision biotechnology company that combines cryogenic electron microscopy (cryo-EM) and machine learning to discover and develop therapeutics by targeting and modulating key protein-protein interactions. Its structure-guided drug discovery platform comprises SPOTLIGHT for target prediction and validation, HYPERFOCUS for hit identification from virtual and fragment libraries, and CRYO-CADD for lead optimization. The company pursues a preclinical oncology program focused on difficult-to-treat cancers with novel protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area of Canada, Gandeeva aims to advance differentiated therapeutics and improve outcomes for patients by leveraging its integrated imaging, modeling, and screening capabilities.
Gameto is a biotechnology company focused on advancing female reproductive health through innovative therapies. Recognizing the significant lack of treatment options in this underserved area, Gameto employs cutting-edge scientific techniques to develop solutions that enhance the quality of life for women. The company utilizes cellular engineering to create a platform that produces engineered ovarian and endometrial cell lines capable of mimicking the functions of natural cells, including hormone production and response. This platform underpins a portfolio of cellular therapeutics aimed at addressing various female reproductive diseases. Gameto's first initiative, Fertilo, targets improvements in in vitro fertilization (IVF) and egg freezing processes, striving to make them shorter, safer, and more effective. Additionally, the company is developing Deovo, an organoid model of the female reproductive system, and Ameno, a cell-based therapy designed to mitigate health issues related to primary ovarian insufficiency and menopause. Through these efforts, Gameto aims to transform the landscape of female reproductive health care.
Eikon Therapeutics
Series B in 2022
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.
Nomic is a bioengineering company developing the nELISA platform for measuring proteins at scale and high throughput. They offer protein profiling solutions empowering scientists to decide experiment scope and scale.
H1 provides a global healthcare platform that connects life sciences companies, hospitals, academic medical centers, and health systems with providers, enables access to clinical research, helps locate industry experts, and supports benchmarking of organizations. As a trusted source of information on healthcare professionals and institutions, the platform combines real-time data and clinical findings to illuminate the broader healthcare ecosystem. The company, founded in 2017 and based in New York, also offers a healthcare data analytics capability that delivers real-time, end-to-end insights across the data landscape to support therapeutic development—from fundraising and product development to product launch.
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
LatchBio
Seed Round in 2021
LatchBio is a biotechnology company founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman. It focuses on developing a data infrastructure aimed at supporting the open-source biocomputing revolution. The company provides a bioinformatics platform specifically designed for cell and gene therapy startups, offering a modern cloud computing stack that enables biotech labs to manage and execute custom workflows, pipelines, and machine learning models. This platform allows scientists to create bioinformatic queries efficiently, without requiring command-line expertise or the burdens of complex system setups. By streamlining data integration and computational processes, LatchBio helps biotech companies accelerate therapeutic discovery and reduce engineering costs.
Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.
AllStripes
Series B in 2021
AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.
Maven Clinic
Series D in 2021
Maven Clinic is an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and the postpartum period. Founded in 2014 and headquartered in New York City, the clinic provides video appointments and private messaging with a network of women's and family health practitioners. Its comprehensive services cater to various needs, including IVF and egg-freezing tracks, pregnancy, postpartum, partner support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and customized training for human resources managers. The company serves individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care solutions.
Mahana Therapeutics
Series B in 2021
Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.
Carbon Health
Series D in 2021
Carbon Health is a technology-enabled healthcare company that delivers primary and virtual care through a mobile app and a network of clinics. It provides omnichannel services, enabling patients to access care via clinics, pop-up sites, video visits, and a single platform for following treatment plans, managing prescriptions, and viewing lab results. The company has developed COVID-19 tools, including an assessment tool and testing in California. Founded in 2015 and headquartered in San Francisco, Carbon Health aims to provide convenient, accessible care from anywhere.
Enveda Biosciences
Series A in 2021
Enveda is a biotechnology company that uses AI-powered tools to explore and characterize molecules from living organisms. It aims to accelerate drug discovery by developing a comprehensive database of chemical biodiversity.
Eikon Therapeutics
Series A in 2021
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
Pawp, Inc. is a digital health clinic and telehealth platform founded in 2020 and based in New York, New York. The company focuses on providing pet owners with 24/7 access to licensed veterinary professionals, enabling them to manage their pets' health effectively. Pawp's services aim to reduce unnecessary veterinary visits by offering expert consultations online, thereby lowering costs for pet owners. Additionally, the company provides a pet emergency fund of $3,000 per year, acting as a financial safety net for unforeseen veterinary expenses. By combining access to veterinary care and emergency funding, Pawp empowers pet owners to make informed health decisions for their pets.
Alife Health
Seed Round in 2021
Alife Health develops artificial intelligence tools for fertility care to improve pregnancy outcomes. The company provides AI-based health technology that helps doctors select the healthiest embryos and supports IVF planning, aiming to increase the likelihood of healthy pregnancies. It connects fertility specialists with patients to streamline IVF treatment and decision making. Founded in 2020 and headquartered in San Francisco, California, the company focuses on applying deep learning and software to reproductive medicine, enabling clinicians to personalize embryo selection and patient care. Alife Health strives to enhance access to effective fertility treatments and assist prospective parents in achieving successful pregnancies.
Multiply Labs
Series A in 2021
Multiply Labs develops robotic-enabled manufacturing for personalized pharmaceutical capsules, combining pharmaceutical science with robotics to produce tailor-made capsules that align with individual patient metabolic needs. The company operates a robotic manufacturing facility and has introduced 3D-printed capsules, aiming to address scaling challenges in biotech and improve the efficiency and cost of producing patient-specific medicines.
Vesta Healthcare
Venture Round in 2021
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.
SteadyMD, Inc. is a provider of online primary care services based in St. Louis, Missouri, with an additional office in Westlake Village, California. Founded in 2016, the company connects patients with board-certified clinicians through a digital platform that facilitates telehealth services for various medical conditions, dietary preferences, and lifestyle choices. Patients can communicate with their doctors via text, call, or video chat, allowing for personalized and comprehensive care. SteadyMD also serves as a telehealth infrastructure provider, enabling healthcare leaders to scale their telehealth offerings across all 50 states by providing a licensed clinician workforce and support in clinical operations, legal, and regulatory matters. The company's innovative approach aims to improve access to high-quality care by addressing the complexities of chronic illnesses and ensuring that patients receive adequate time and attention from their healthcare providers.
DeepSpin
Convertible Note in 2021
DeepSpin GmbH, founded in 2019 and based in Berlin, Germany, specializes in the development of an innovative artificial intelligence-powered magnetic resonance imaging (MRI) system. The company's technology aims to significantly reduce the cost, size, and weight of traditional MRI machines, thereby enhancing accessibility to medical imaging for patients worldwide. By utilizing generative topological design for its hardware and deep learning techniques for image processing, DeepSpin's MRI system seeks to make advanced medical imaging available in a variety of previously underserved healthcare settings. This approach not only aims to improve patient care but also to democratize access to essential medical diagnostics globally.
Senti Biosciences
Series B in 2021
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
H1 provides a global healthcare platform that connects life sciences companies, hospitals, academic medical centers, and health systems with providers, enables access to clinical research, helps locate industry experts, and supports benchmarking of organizations. As a trusted source of information on healthcare professionals and institutions, the platform combines real-time data and clinical findings to illuminate the broader healthcare ecosystem. The company, founded in 2017 and based in New York, also offers a healthcare data analytics capability that delivers real-time, end-to-end insights across the data landscape to support therapeutic development—from fundraising and product development to product launch.
Workit Health
Series B in 2020
Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.
National Resilience
Series B in 2020
National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.
Paceline
Seed Round in 2020
Paceline is bringing together the worlds of health & wellness and financial services to change the nature of preventive health in society. We’re building a best-in-class fitness rewards platform and innovative financial ecosystem, powered by physical activity, with the goal of helping people live longer, healthier, and better lives.
Auransa Inc. is a clinical stage drug development company founded in 2014 and based in Palo Alto, California. The company focuses on inventing novel drugs for challenging diseases, including cancer, autoimmune disorders, and neurological conditions, utilizing its proprietary AI-driven drug discovery platform. This platform enables Auransa to analyze extensive genomics data from human disease tissues, facilitating the study of molecular disease subtypes and the prediction of effective compounds and targets for specific patient populations. Auransa's current pipeline includes a first-in-class investigational new drug for cancer that is undergoing clinical trials. Additionally, the company collaborates with various partners in the biopharma industry to enhance its research and development efforts.
Science 37
Venture Round in 2020
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
Thrive Earlier Detection
Series B in 2020
Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.
Braid Health
Series A in 2020
Braid Health, Inc. is a digital health innovation company founded in 2018 and based in San Francisco, California. It specializes in developing artificial intelligence-driven diagnostic tools specifically for radiology. By creating an AI-powered diagnostic collaboration platform, Braid Health enhances the speed, quality, and workflow of radiologists and healthcare providers. The company’s systems integrate AI diagnostics with the expertise of board-certified radiologists, facilitating real-time quality assurance and seamless Electronic Health Records (EHR) integration. This approach enables healthcare professionals to deliver accurate diagnoses efficiently, ultimately improving the quality of patient care.
Mahana Therapeutics
Series A in 2020
Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.
AllStripes
Series A in 2020
AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.
Avail Medsystems
Series A in 2020
Avail Medsystems, Inc. is a digital healthcare company based in Palo Alto, California, that specializes in developing a comprehensive hardware and software platform designed to connect healthcare professionals remotely. The company offers a fully integrated audio/visual system that facilitates real-time collaboration and procedural support, enabling practitioners to access clinical expertise and education without the constraints of physical location. By democratizing access to specialized knowledge and services, Avail Medsystems enhances the efficiency of healthcare delivery and promotes the adoption of innovative medical technologies. Founded in 2012 and previously known as Nurep, Inc., the company aims to improve patient care by bridging gaps between healthcare providers and medical technology experts.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.
Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.
Vesta Healthcare
Series A in 2020
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.
Mahana Therapeutics
Seed Round in 2020
Mahana Therapeutics, Inc. is a company focused on developing digital treatments for individuals with chronic health conditions, particularly gastrointestinal diseases. Its flagship offering, Parallel, is a clinically validated, minimal-contact digital program specifically designed for patients suffering from irritable bowel syndrome (IBS). The program aims to deliver both physical and psychological support to enhance patient well-being. Founded in 2018 and headquartered in San Francisco, California, Mahana Therapeutics also maintains an office in London, United Kingdom. The company was previously known as Mahana Health, Inc. before rebranding in July 2019.
Cajal Neuroscience
Seed Round in 2020
Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.
HumanFirst
Seed Round in 2019
HumanFirst is a company focused on enhancing patient-centered clinical trials through its advanced precision measures platform, which is recognized as the world's largest AI-powered software-as-a-service solution for improving health outcomes. The platform offers insights and validated evidence data to support biopharmaceutical companies in their drug development processes, enabling them to incorporate digital health technologies, digital biomarkers, and electronic clinical outcome assessments. By providing industry educational tools and facilitating collaboration with research partners, HumanFirst helps biopharma organizations increase research efficiency and accelerate the deployment of innovative treatments. The platform has been utilized by a significant majority of the largest pharmaceutical companies globally, underscoring its role in transforming clinical research and driving the evolution of drug development.
Variant Bio
Series A in 2019
Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.
Cala Health
Series C in 2019
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.
Zipdrug
Venture Round in 2019
Zipdrug, Inc. is a technology company that has developed an application aimed at simplifying the process of ordering prescribed medications. Founded in 2015 and based in New York City, the company provides a platform that connects patients with a curated network of pharmacies, allowing for the delivery of prescriptions directly to their homes. This service is particularly beneficial for Medicare and Medicaid members, as it facilitates access to low-cost pharmacies and promotes medication adherence through personalized care. By eliminating the waiting time typically associated with traditional pharmacy visits, Zipdrug enhances the overall patient experience in managing their prescriptions. As of July 2020, Zipdrug operates as a subsidiary of IngenioRx, Inc.
Workit Health
Series A in 2019
Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.
Science 37
Series D in 2019
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
Eikon Therapeutics
Seed Round in 2019
Eikon Therapeutics is a biopharmaceutical company that uses proprietary live-cell imaging platforms to discover and develop therapeutics for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company applies super-resolution, single-molecule, and real-time molecular-resolution observations to study how compounds interact with individual proteins in living cells. By integrating biology, engineering, and chemistry, Eikon seeks to identify previously intractable targets, accelerate the drug-discovery process, and expand its clinical pipeline through platforms that reveal target biology and compound-protein interactions in their native cellular context.
Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.
Vesta Healthcare
Series A in 2018
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.
Auris Health
Series E in 2018
Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.
Visla Labs
Seed Round in 2018
Visla Labs Inc. is a San Francisco-based company established in 2018 that focuses on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. The company aims to innovate and enhance healthcare delivery through advanced AI technologies, positioning itself as a key player in the evolving landscape of medical diagnostics and patient care. With venture capital support, Visla Labs is poised for significant growth and is working towards achieving critical milestones in its development.
Braid Health
Seed Round in 2018
Braid Health, Inc. is a digital health innovation company founded in 2018 and based in San Francisco, California. It specializes in developing artificial intelligence-driven diagnostic tools specifically for radiology. By creating an AI-powered diagnostic collaboration platform, Braid Health enhances the speed, quality, and workflow of radiologists and healthcare providers. The company’s systems integrate AI diagnostics with the expertise of board-certified radiologists, facilitating real-time quality assurance and seamless Electronic Health Records (EHR) integration. This approach enables healthcare professionals to deliver accurate diagnoses efficiently, ultimately improving the quality of patient care.
AllStripes
Seed Round in 2018
AllStripes is a healthcare technology company focused on accelerating the development of new treatments for rare diseases. The company has created a platform that enables the generation of regulatory-ready evidence, facilitating rare disease research and drug development. AllStripes operates a two-sided network that connects patients with rare diseases and advocacy groups to life science companies seeking new drug candidates. Through this network, patients can contribute their medical data and participate in treatment research online, while life science companies gain access to valuable data and insights to support their drug development efforts.
Rivet Health, Inc. is a company specializing in healthcare revenue cycle management through its software-as-a-service platform. Founded in 2018 and based in Cottonwood Heights, Utah, Rivet provides tools that enhance financial transparency and operational efficiency for healthcare providers and patients. Its offerings include features that allow providers to quote and collect patient costs upfront and manage payer contracts effectively. The software also helps patients understand their financial responsibilities, detect underpayments, and create accurate estimates, thereby fostering better communication between providers and payers. By addressing the complexities of healthcare transactions, Rivet aims to improve the overall experience for both patients and providers.
Kyruus
Corporate Round in 2018
Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.
Senti Biosciences
Series A in 2018
Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.
Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.
Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.
Physera
Seed Round in 2017
Physera, Inc. is a healthcare company focused on providing digital solutions for patients with musculoskeletal injuries. Founded in 2015 and based in Palo Alto, California, Physera offers a mobile application that connects patients to licensed physical therapists for remote diagnosis and treatment. The platform features video access to therapists, as well as in-app animations, voice prompts, and digital exercise therapy designed to alleviate musculoskeletal pain. By collecting data on patient progress and treatment effectiveness, the application allows therapists to tailor recovery and maintenance plans to individual needs. Physera serves a diverse clientele that includes patients suffering from muscular pain, self-insured employers, and large health plans. As of May 2020, Physera operates as a subsidiary of Omada Health, Inc.
Octant Bio
Seed Round in 2017
Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.
Auris Health
Series D in 2017
Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.
Science 37
Series C in 2017
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
Science 37
Series B in 2016
Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.
Workit Health
Seed Round in 2016
Workit Health provides online therapeutic content and professional counseling services for substance use recovery. It offers Workit, an interactive platform for individuals seeking to reduce or quit alcohol consumption, providing discreet access to on-demand medical and psychosocial support.
3Scan develops robotic microscopy tools and software for large-scale tissue analysis and three-dimensional visualization. It builds devices that automate tissue sectioning and integrates automation with machine learning and computer vision to extract spatial data from tissue and generate detailed three-dimensional representations and quantitative analyses of complex anatomical structures. These capabilities enable higher-throughput histology and broader image analysis for researchers and clinicians, supporting advances in diagnostics and therapeutics for diseases such as cancer, neurodegenerative conditions, and cardiovascular disease.
Cala Health
Series B in 2016
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.